Reviewed by Dr. Elena Vance, DOLast reviewed 15 sources cited
Quick Summary
Rybelsus (semaglutide) and Zepbound (tirzepatide) are both incretin-based therapies. In clinical trials, Zepbound showed greater weight loss (22.5% vs 4.4%).
See the comparison table below for detailed side-by-side data.
Rybelsus vs Zepbound: Full Comparison
| Feature | Rybelsus(semaglutide) | Zepbound(tirzepatide) |
|---|---|---|
| Active Ingredient | semaglutide | tirzepatide |
| Drug Class | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| Manufacturer | Novo Nordisk | Eli Lilly |
| FDA Approved | 2019-09-20 | 2023-11-08 |
| Approved Indications |
|
|
| Route | oral | subcutaneous injection |
| Frequency | Once daily | Once weekly |
| Starting Dose | 3 mg daily | 2.5 mg weekly |
| Maintenance Dose | 7 mg or 14 mg daily | 5 mg, 10 mg, or 15 mg weekly |
| Max Dose | 14 mg daily | 15 mg weekly |
| Weight Loss (%) | 4.4% | 22.5% |
| A1C Reduction | 1.4% | N/A (not indicated for diabetes) |
| Key Trial | PIONEER 1 (26 weeks) | SURMOUNT-1 / SURMOUNT-5 (head-to-head vs semaglutide) (72 weeks) |
| List Price | $935-$1,029/month | $1,060-$1,176/month |
| With Insurance | $25-$150/month (varies by plan) | $25-$250/month (varies; weight-loss coverage is limited) |
| Savings Card | $10/month (Novo Nordisk savings card, commercially insured) | $25/month (Lilly savings card, commercially insured) |
Side Effects: Rybelsus vs Zepbound
| Side Effect | Rybelsus | Zepbound |
|---|---|---|
| Nausea | 11-20% | 24-33% |
| Abdominal pain | 5-11% | 10-14% |
| Diarrhea | 5-10% | 18-25% |
| Decreased appetite | 3-9% | Not reported |
| Vomiting | 4-8% | 10-18% |
| Constipation | 3-5% | 13-17% |
| Pancreatitis (rare) | <0.5% | <1% |
| Dyspepsia | Not reported | 7-10% |
| Injection site reaction | Not reported | 3-7% |
| Hair loss | Not reported | 5-6% |
| Gallbladder events | Not reported | 1.6% |
Severity scale: 1 (mild) to 5 (serious). Based on FDA prescribing information and clinical trial data.
Related Comparisons
Frequently Asked Questions
Sources & References
FDA & Regulatory
Clinical Trial Records
Peer-Reviewed Literature
- Aroda VR et al. PIONEER 1: Oral Semaglutide Monotherapy vs Placebo in Type 2 Diabetes. Diabetes Care 2019;42:1724-1732 — Diabetes Care
- Husain M et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (PIONEER 6). N Engl J Med 2019;381:841-851 — New England Journal of Medicine
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216 — New England Journal of Medicine
- Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). N Engl J Med 2024;391:1193-1205 — New England Journal of Medicine
Safety Communications
Manufacturer Information
- Rybelsus patient and healthcare provider website — Novo Nordisk
- Zepbound patient and healthcare provider website — Eli Lilly
- Lilly lowers price of Zepbound single-dose vials (December 1, 2025) — Eli Lilly Investor Relations
- SURMOUNT-5: Zepbound superior weight loss over Wegovy (May 11, 2025) — Eli Lilly Investor Relations
This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.